Technology & Platform

eFlow® Technology

In order to meet patients‘ need for silent, fast and efficient delivery of nebulised liquid drug products, PARI developed the eFlow Technology.

A core component of all eFlow Technology nebulisers is a laser drilled, vibrating membrane made from stainless steel. Using a tightly controlled laser drilling process, the geometry of the holes in the membrane can be adjusted to certain formulations to produce aerosols with specific characteristics for optimised respiratory delivery.

All eFlow Technology nebulisers for spontaneously breathing patients utilise a patented aerosol chamber with inspiratory and expiratory valves. The aerosol is generated continuously into this chamber by the vibrating membrane. During the inhalation phase, the aerosol is inhaled as emitted from the vibrating membrane while it is stored in the aerosol chamber during the exhalation phase (the patient’s exhaled air escapes through the expiratory valve). The stored aerosol is inhaled as a dense aerosol bolus at the onset of the following inhalation. This design reduces nebulisation time and increases delivery efficiency as the aerosol produced during the exhalation phase is largely conserved in the chamber and delivered to the patient.

eFlow® Technology platform

PARI’s engineers design solutions to adapt the eFlow® Technology platform to various needs of specific drug products, applications and patient populations. This includes options to tailor the nebuliser to:

  • Disease-specific breathing patterns
  • Deposition of aerosol droplets in different regions of the lungs
  • Enable supplemental oxygen during aerosol therapy
  • Diverse age groups (from pre-maturely born neonates to children, adolescents, adults and elderly patients)
  • Spontaneously breathing or mechanically ventilated patients
  • Upper or lower respiratory tract drug delivery
  • Systemic drug delivery via the lungs

Video about the eFlow® Technology nebuliser system

Watch this video to learn about the eFlow® Technology nebuliser system (Open System) and its unique components.

Aerosolisation of a broad variety of formulations

Both the eFlow® and Vibrent® Technology can be adjusted to successfully nebulise a variety of molecules and formulations with a broad range of fill volumes and physicochemical properties, including:

  • Small molecules (e.g. Glycopyrrolate, Tobramycin, Levofloxacin and others)
  • Protein formulations (e.g. Alpha-1-Antitrypsin)
  • Peptides (e.g. POL6014),
  • Oligonucleotides (e.g. Eluforsen QR-010)
  • Suspensions including liposomal formulations (e.g. Liposomal Amikacin, Liposomal Cyclosporine A)

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!


I have acknowledged the information regarding data processing.